Comparative Pharmacology
Head-to-head clinical analysis: ELAHERE versus FOLEX PFS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELAHERE versus FOLEX PFS.
ELAHERE vs FOLEX PFS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ELAHERE (mirvetuximab soravtansine) is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). It consists of a humanized anti-FRα antibody conjugated to the maytansinoid DM4, a microtubule inhibitor. Upon binding to FRα on tumor cells, the ADC is internalized and releases DM4, which binds to tubulin and disrupts microtubule polymerization, leading to cell cycle arrest and apoptosis.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the synthesis of tetrahydrofolate and thereby interfering with DNA synthesis, repair, and cellular replication. It also exhibits immunosuppressive and anti-inflammatory effects through inhibition of purine and pyrimidine synthesis and reduction of cytokine production.
6 mg/kg adjusted ideal body weight intravenously every 3 weeks until disease progression or unacceptable toxicity.
Methotrexate 30-40 mg/m2 IV once weekly or 7.5-15 mg PO once weekly as single dose or divided into 3 doses over 24 hours.
None Documented
None Documented
Terminal half-life approximately 6.2 days (range 3.7-9.5 days) after IV administration; supports every-3-week dosing interval.
Terminal elimination half-life: 6-12 hours in patients with normal renal function. With impaired renal function, half-life is prolonged (up to 24-48 hours). Low-dose methotrexate (e.g., for rheumatoid arthritis) has half-life 3-10 hours. High-dose methotrexate has a triphasic elimination: alpha phase (0.75 hours), beta phase (3.5 hours), and terminal gamma phase (10-20 hours).
Fecal (approximately 80%) as unchanged drug; renal (approximately 8%) as unchanged drug and metabolites.
Primarily renal excretion as unchanged drug; approximately 80-90% excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<10%).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent